Prognostic significance of osteopontin expression in human prostate cancer

International Journal of Cancer

Volumn 118, Issue 9, 2006, Pages 2255-2261

  Forootan, Shiva S ^a   Foster, Christopher S ^a   Aachi, Vijay R ^a   Adamson, Janet ^a   Smith, Paul H ^a   Lin, Ke ^a   Ke, Youqiang ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Benign prostate hyperplasia (BPH); Gleason scores; Osteopontin; Patient survival; Prostate carcinoma

Indexed keywords

GLYCOPROTEIN; INTEGRIN; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SURVIVAL TIME; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 33645664267     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21619     Document Type: Article

References (32)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;41:8-31.
2. Foster CS, Comford P, Forsyth L, Djamgoz MBA, Ke Y. The cellular and molecular basis of prostate cancer. Br J Urol 1999;83:171-94.
3. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005;58:673-84.
4. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signalling pathways in breast cancer cells. J Biol Chem 2003;278:28593-606.
5. Medico E, Gentile A, Lo CC, Williams TA, Gambarotta G, Trusolino L, Comoglio PM. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 2001;61:5861-68.
6. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 2000;78:465-75.
7. Tuck AB, Hota C, Wilson SM, Chambers AF. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003;22:1198-205.
8. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998;79:502-08.
9. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000;83:156-63.
10. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated Serum bone sialoprotein and osteopontin in colon, breast, prostate and lung cancer. Clin Cancer Res 2001;7:4060-66.
11. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LWK. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999;5:2271-77.
12. Tozawa K, Yamada Y, Kawai N, Okamura T, Ueda K, Kohri K. Osteopontin expression in prostate cancer and benign prostatic hyperplasia. Urologia Int 1999;62:155-58.
13. Berthon P, Cussenot O, Hopwood L, Le Due A, Maitland NJ. Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumorigenic cell lines. Int J Oncol 1995;6:333-43.
14. Cussenot O, Berthon P, Berger R, Mowszowicz I, Faille A, Hojman F, Teillac P, Le Due A, Calvo F. Immortalization of human adult normal prostatic epithelial cells by liposomes containing Large T-SV40 gene. J Urol 1991;143:881-86.
15. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy G. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
16. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of human prostate carcinoma cell line (Du-145). Int J Cancer 1978;21:274-81.
17. Kaighn ME, Lechner JF, Narayan KS, Jones LW. Prostate carcinoma: tissue culture cell lines. Natl Cancer Inst Monogr 1978;49:17-21.
18. Ke Y, Jing C, Barraclough R, Smith P, Davies MPA, Foster CS. Elevated expression of calcium-binding protein p9ka is associated with increasing malignant characteristics of rat prostate carcinoma cells. Int J Cancer 1997;71:827-37.
19. Deshmukh N, Scotson J, Dodson AR, Ke YQ, Foster CS. Differential expression of acidic- and basic-FGF in benign prostatic hyperplasia identified by immunohistochemistry. Br J Urol 1997;80:869-74.
20. Gleason D, Mellinger G. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
21. Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, Fujii H, Smith PS, Ke Y. Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. Cancer Res 2001;61:4357-64.
22. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin β15: a novel regulator of tumour cell motility upregulated in metastatic prostate cancer. Nat Med 1996;2:1322-28.
23. Jing C, El-Ghany MA, Beesley C, Foster CS, Rudland PS, Smith P, Ke Y. Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst 2002;94:482-90.
24. Jing C, Beesley C, Foster CS, Rudland PS, Fujii H, Ono T, Chen H, Smith PH, Ke Y. Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer. Cancer Res 2000;60:2390-98.
25. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Mairtignetti JA, et al. KLF6, a candidate tumour suppresor gene mutated in prostate cancer. Science 2001;294:2563-66.
26. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-29.
27. Lorente JA, Arango O, Bielsa O, Cortadellas R, Gelabert-Mas A. Effect of antibiotic treatment on serum PSA and percent free PSA levels in patients with biochemical criteria for prostate biopsy and previous lower urinary tract infections. Int J Biol Markers 2002;17:84-89.
28. Wai PY, Kuo PC. The role of osteopontin in tumour metastasis. J Surg Res 2004;121:228-41.
29. Angelucci A, Festuccia C, Gravina GL, Muzi P, Bonghi L, Vicentini C, Bologna M. Osteopontin enhance the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 2004;59:167-66.
30. Adamson J, Morgan EA, Beesley C, Mei YQ, Foster CS, Fujii H, Rudland PS, Smith P, Ke Y. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene 2003;22:2739-49.
31. Smith P, Rhodes NP, Ke Y, Foster CS. Sodium channel protein expression is related to metastatic potential of rat and human prostate cancer cells. FEBS Lett 1998;423:19-24.
32. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin, associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Am Cancer Soc 2002;95:506-12.